PAI-1在慢性肾脏病患者肾组织中表达的临床意义

Effects of Valsartan on Expression of PAI-1 in Renal Tissue in Patients with CKD

目的:探讨纤溶酶原激活物抑制物-1(PAI-1)在慢性肾脏病(CKD)患者肾组织中表达的临床意义。方法:采用免疫组化法检测63例CKD患者肾穿刺标本(CKD组)及19例正常肾组织(对照组)中PAI-1的表达水平。比较PAI-1在对照组及不同分期的CKD组患者中的表达差异,并比较16例使用缬沙坦治疗的CKD患者与47例未使用缬沙坦治疗的CKD患者中肾组织PAI-1表达的差异。结果:CKD组患者不同分期PAI-1在肾组织中的表达均较对照组显著增多(P<0.05);而CKD3期PAI-1在肾组织的表达明显高于CKD1、2期(P<0.05);使用过缬沙坦治疗的CKD患者肾组织中PAI-1的表达明显低于未使用缬沙坦治疗的患者,差异有统计学意义(P<0.05)。结论:CKD患者肾组织中存在PAI-1的过度表达,其有助于判断CKD患者的肾功能损害程度及预后;缬沙坦通过抑制PAI-1的产生而阻止肾脏的炎症和纤维化,有助于慢性肾脏疾病的防治。

OBJECTIVE： To evaluate the expression on plasminogen activator inhibitor-1 （PAI-1） in the human renal biopsy of patients with CKD and analyze its clinical significance. METHODS： The expression of PAI-1 in 63 specimens of patients with CKD（CKD group） and 19 normal renal tissue（Control group） were detected by immuno-histochemistry. The expression of PAl-1 in the normal renal tissue were compared with the each phase CKD group. Meanwhile, The expression of PAI-1 in 16 patients with CKD treated by valsartan were compared with 47 cases not treated. RESULTS： Compare with the control group, the expression of PAI-1 in each phase CKD group was respectively drastically increased （P〈0.05）. The expression of PAI-1 in Phase 3 CKD was significant higher than that of Phase 1 CKD and Phase 2 CKD （P〈0.05）. The expression of PAl-1 in the group treated by valsartan was lower than that of the group not treated （P〈0.05）. CONCLUSION： The abnormal expression of PAI-1 in renal tissue in patients with CKD plays an important role in the prognosis and identification of impairment of renal fuction. Valsartan inhibits the development of renal inflammation and sclerosis by controlling the formation of PAI-1 so as to prevent and treat CKD.